📣 VC round data is live. Check it out!
- Public Comps
- CEL
CEL Valuation Multiples
Discover revenue and EBITDA valuation multiples for CEL and similar public comparables like Atlantic International, Rapid Micro Biosystems, Fonet, Exagen and more.
CEL Overview
About CEL
CEL Corp is engaged in the rental housing business that provides apartment management proposals, apartment designs and apartment construction management services, rental housing development business, rental management business entrusted with apartment management, and Renovation business.
Founded
1993
HQ

Employees
186
Website
Sectors
Financials (LTM)
Market Cap
$106M
Valuation Multiples
Start free trialCEL Financials
CEL reported last 12-month revenue of $127M.
In the same LTM period, CEL generated $7M in net income.
CEL P&L
In the most recent fiscal year, CEL reported revenue of $153M and EBITDA of $14M.
CEL is profitable as of last fiscal year, with gross margin of 20%, EBITDA margin of 9%, and net margin of 6%.
Financial data powered by Morningstar, Inc.
CEL Stock Performance
CEL has current market cap of $106M.
CEL's stock price is $31.28.
CEL has an EPS (earnings per share) of $2.67.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $106M | 0.1% | — | — | — | $2.67 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCEL Valuation Multiples
CEL trades at (0.0x) EV/Revenue multiple, and (0.3x) EV/EBITDA.
CEL Financial Valuation Multiples
As of May 10, 2026, CEL has market cap of $106M.
CEL has a P/E ratio of 14.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified CEL Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


CEL Margins & Growth Rates
CEL decreased revenue by 17% and net profit by 20% in the last fiscal year.
In the most recent fiscal year, CEL reported gross margin of 20%, EBITDA margin of 9%, and net margin of 6%.
CEL Margins
CEL Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
CEL Operational KPIs
CEL's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.1M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
CEL Competitors
CEL competitors include Atlantic International, Rapid Micro Biosystems, Fonet, Exagen, BATM Advanced Communications, BICO Group, Anatolia Geneworks, Gentian Diagnostics, Daxor and Biodesix.
Most CEL public comparables operate across Laboratory Services.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.5x | 0.5x | (4.7x) | — | |||
| 3.2x | 3.0x | (2.5x) | (2.5x) | |||
| 6.5x | — | 13.1x | — | |||
| 1.0x | 0.9x | (6.6x) | (7.3x) | |||
| 0.5x | 0.5x | 2.9x | 4.1x | |||
| 0.8x | 0.8x | 67.2x | 31.7x | |||
| 4.5x | — | (33.1x) | — | |||
| 3.0x | 2.8x | 14.7x | 14.2x | |||
This data is available for Pro users. Sign up to see all CEL competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout CEL
| When was CEL founded? | CEL was founded in 1993. |
| Where is CEL headquartered? | CEL is headquartered in Japan. |
| How many employees does CEL have? | As of today, CEL has over 186 employees. |
| Is CEL publicly listed? | Yes, CEL is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of CEL? | CEL trades under 5078 ticker. |
| When did CEL go public? | CEL went public in 2022. |
| Who are competitors of CEL? | CEL main competitors include Atlantic International, Rapid Micro Biosystems, Fonet, Exagen, BATM Advanced Communications, BICO Group, Anatolia Geneworks, Gentian Diagnostics, Daxor, Biodesix. |
| What is the current market cap of CEL? | CEL's current market cap is $106M. |
| What is the current revenue of CEL? | CEL's last 12 months revenue is $127M. |
| What is the current revenue growth of CEL? | CEL revenue growth (vs. last FY) is (17%). |
| What is the current EV/Revenue multiple of CEL? | Current revenue multiple of CEL is (0.0x). |
| Is CEL profitable? | Yes, CEL is net-income-positive (as of the last 12 months). |
| What is the current net income of CEL? | CEL's last 12 months net income is $7M. |
| How many companies CEL has acquired to date? | CEL hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies CEL has invested to date? | CEL hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to CEL
Lists including CEL
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.